A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170).

Edward B Maldonado W Kimryn Rathmell Geoffrey I Shapiro Naoko Takebe Jordi Rodon Ahnert Devalingam Mahalingam Nikolaos A Trikalinos Arash Rezazadeh Kalebasty Mamta Parikh Scott A Boerner Celene Balido Gregor Krings Timothy F Burns Emily K Bergsland Pamela N Munster Alan Ashworth Patricia M LoRusso Rahul R Aggarwal

Published in: Cancer research communications (2024)

WEE1 inhibition with adavosertib monotherapy demonstrated limited clinical activity in patients with SETD2-altered solid tumors despite compelling preclinical data indicating a synthetic lethal effect, which did not translate into robust tumor regression. Loss of the H3K36me3 trimethylation mark caused by SETD2-deficiency was confirmed in the majority of evaluable tumors. A subset of patients derived clinical benefit as manifested by minor tumor regressions and prolonged SD.

Keyphrases

end stage renal disease
chronic kidney disease
newly diagnosed
open label
prognostic factors
stem cells
clinical trial
peritoneal dialysis